Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 7/20 | 0.39 |
| ▸ | POLR1A | O95602 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.36 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.36 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.35 |
| ▸ | AXL | P30530 | 4/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30386128 | 0.97 | TTK (0.38) | TTKPOLR1AEGFRERBB2ERBB3 | |
| SCHEMBL30386170 | 0.96 | TTK (0.38) | TTKPOLR1AEGFRERBB2ERBB3 | |
| SCHEMBL25173677 | 0.91 | TTK (0.40) | TTKPTK6AXL | |
| SCHEMBL30385495 | 0.90 | TTK (0.43) | TTKAXL | |
| SCHEMBL22123681 | 0.90 | TTK (0.39) | TTKPTK6AXL | |
| SCHEMBL30385437 | 0.89 | TP53 (0.40) | PTK6JAK2JAK3PTK2 | |
| SCHEMBL25176176 | 0.88 | TTK (0.37) | TTKPTK6AXL | |
| SCHEMBL30385715 | 0.88 | TTK (0.33) | TTKEGFRERBB2ERBB3ERBB4 | |
| SCHEMBL22139189 | 0.88 | TTK (0.43) | TTKAXL | |
| SCHEMBL30385499 | 0.87 | TP53 (0.38) | TTKPTK6USP30JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | IKZF3, RRP15, IK | TTK 4336/4885POLR1A 1654/4885EGFR 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.